One third of those polled said their vaccine decisions do not affect others.
Levels of the HV.1 subvariant, part of the Omicron EG.5 family, were most common and continue to rise
The WHO lowered its treatment-benefit threshold from a 6% to a 2% reduction in the risk of hospitalization.
Exemptions increased in 41 states, and exceeded 5% in 10 states.
Up-to-date COVID-19 vaccination coverage was 17% among hospital healthcare personnel and 23% among those at nursing homes.
In the small cohort study, 88 patients with loss of smell and taste were compared to 88 controls.
The study was based on findings among a cohort of 60,456 solid-organ transplant recipients in France.
The Traveler-based Genomic Surveillance program will expand to provide early detection of flu and other respiratory viruses.
The study data from the sixth wave of COVID-19 cases seen in Tokyo caused by BA.1 and BA.2 from January to May 2022.
The study was based on information gleaned from the UK Biobank, which included health information on 151,200 adults.
On the third day of illness, 19% of participants worked remotely during the pandemic, compared with 9% before.
COVID-related hospitalizations are up a bit, flu-like illness is climbing, and officials confirm more avian flu outbreaks on poultry farms in 5 states.
In the first pandemic year, executive function and working memory were significantly worse across the cohort.
The proportion of respondents who believe in the safety of vaccines fell from 77% in April 2021 to 71% in fall 2023.
Cruise ships became one of the first sites of COVID-19 outbreaks in the spring of 2020.
No effect was seen on women's or men's vaccination status and miscarriage rates.
The only benefit seen was a lowered combined risk for venous thromboembolism.
The estimated percentage of JN.1 viruses is very small—about 0.1%.
The analysis included 806 patients who were infected with the wild-type strain, Alpha, Delta, or Omicron strain.
The researchers estimated 1 in 30 hospitalizations among newly infected adults aged 80 years and older.
Thirty-day death rates were 8% in the Omicron group, 3% in flu patients, and 6% in the RSV group.
Formulations of the combo vaccines prompted robust immune responses against influenza A, influenza B, and SARS-CoV-2.
While antibiotic use at three Chicago hospitals increased in COVID-19 patients at the outset of the pandemic, it declined among non–COVID patients.
Relative vaccine effectiveness was an additional 50% against critical illness.
The study was based on outcomes seen among 660,000 UK patients from February 2020 to April 2021.